Avenue Therapeutics, Inc. (ATXI): Price and Financial Metrics


Avenue Therapeutics, Inc. (ATXI): $1.48

0.06 (+4.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ATXI Stock Price Chart Interactive Chart >

Price chart for ATXI

ATXI Price/Volume Stats

Current price $1.48 52-week high $20.40
Prev. close $1.42 52-week low $1.24
Day low $1.38 Volume 273,400
Day high $1.53 Avg. volume 1,325,167
50-day MA $3.33 Dividend yield N/A
200-day MA $4.87 Market Cap 7.07M

Avenue Therapeutics, Inc. (ATXI) Company Bio


Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. Its product candidate is IV Tramadol for the treatment of post-operative pain. The company was founded in 2015 and is based in New York, New York.


ATXI Latest News Stream


Event/Time News Detail
Loading, please wait...

ATXI Latest Social Stream


Loading social stream, please wait...

View Full ATXI Social Stream

Latest ATXI News From Around the Web

Below are the latest news stories about AVENUE THERAPEUTICS INC that investors may wish to consider to help them evaluate ATXI as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day with an overview of the biggest pre-market stock movers traders need to know about for Thursday!

William White on InvestorPlace | November 10, 2022

Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases (“CNS”), today reported financial results and recent corporate highlights for the third quarter ended September 30, 2022. “I am pleased that Avenue has achieved important financial milestones providing a path to continue developing drug

Yahoo | November 10, 2022

Avenue Therapeutics Buys Baergic Bio, Beefs Up Central Nervous System-Focused Portfolio

Avenue Therapeutics Inc (NASDAQ: ATXI) acquired Baergic Bio Inc pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech Inc (NASDAQ: FBIO). Founded in December 2019, Baergic Bio focuses on developing a pharmaceutical product for CNS disorders. Its pipeline currently includes a single compound, BAER-101, an oral small molecule selective GABA-A α2/3 receptor positive allosteric modulator, which was in-licensed from AstraZeneca Plc (NASDAQ: AZN).

Yahoo | November 8, 2022

Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders

NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system (“CNS”) diseases, today announced the closing of the acquisition of Baergic Bio, Inc. (“Baergic Bio”) pursuant to the previously disclosed Share Contribution Agreement with its parent company, Fortress Biotech, Inc. Founded in December 2019, Bae

Yahoo | November 8, 2022

Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI)

Aegis Capital Corp. acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI).

Yahoo | October 12, 2022

Read More 'ATXI' Stories Here

ATXI Price Returns

1-mo -16.85%
3-mo -57.10%
6-mo -63.95%
1-year -92.47%
3-year -98.34%
5-year -97.53%
YTD -89.13%
2021 -84.74%
2020 -38.02%
2019 77.78%
2018 49.17%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7214 seconds.